Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast ; volume:11 ; number:4 ; day:29 ; month:9 ; year:2023 ; pages:411-418 ; date:12.2023
Oncology and Therapy ; 11, Heft 4 (29.9.2023), 411-418, 12.2023
- Urheber
-
Dong, Brian
Lusen, Rita
Chick, Ella
Kline, Lisa
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-023-00237-4
- URN
-
urn:nbn:de:101:1-2024020714500552257618
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dong, Brian
- Lusen, Rita
- Chick, Ella
- Kline, Lisa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Aromatase inhibitors
Aromatase inhibitors
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Aromatase inhibitors in post-menopausal endometriosis
CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Use of aromatase inhibitors in practice of gynecology
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
Aromatase inhibitors
Aromatase inhibitors
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Aromatase inhibitors in post-menopausal endometriosis
CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Use of aromatase inhibitors in practice of gynecology
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
Aromatase inhibitors
Aromatase inhibitors
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Aromatase inhibitors in post-menopausal endometriosis
CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Use of aromatase inhibitors in practice of gynecology